Flavored, Oral Irinotecan (VAL-413) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Conditions: Solid Tumors; Neuroblastoma; Rhabdomyosarcoma; Ewing Sarcoma; Hepatoblastoma; Medulloblastoma Interventions: Drug: VAL-413; Drug: Temozolomide Sponsor: Valent Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Brain | Hepatoblastoma | Medulloblastoma | Neuroblastoma | Neurology | Pediatrics | Research | Rhabdomyosarcoma | Sarcomas | Temodar